Hood River Capital Management LLC Acquires New Position in Enovis Co. (NYSE:ENOV)

Hood River Capital Management LLC purchased a new position in shares of Enovis Co. (NYSE:ENOV - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 661,430 shares of the company's stock, valued at approximately $29,024,000. Hood River Capital Management LLC owned about 1.16% of Enovis at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Barclays PLC grew its holdings in Enovis by 16.1% during the third quarter. Barclays PLC now owns 368,488 shares of the company's stock worth $15,864,000 after acquiring an additional 51,151 shares during the period. Geode Capital Management LLC boosted its position in Enovis by 9.5% in the 3rd quarter. Geode Capital Management LLC now owns 921,437 shares of the company's stock worth $39,678,000 after purchasing an additional 80,165 shares in the last quarter. Retirement Systems of Alabama grew its stake in shares of Enovis by 10.1% during the 3rd quarter. Retirement Systems of Alabama now owns 67,846 shares of the company's stock worth $2,921,000 after purchasing an additional 6,239 shares during the period. Confluence Investment Management LLC purchased a new position in shares of Enovis during the 4th quarter valued at approximately $3,494,000. Finally, Fiduciary Financial Group LLC acquired a new position in shares of Enovis in the 4th quarter valued at $268,000. 98.45% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Needham & Company LLC restated a "buy" rating and set a $64.00 price target on shares of Enovis in a research report on Wednesday, April 9th.

Enovis Price Performance

Shares of ENOV stock traded down $0.11 during trading hours on Friday, hitting $35.01. 890,659 shares of the company's stock were exchanged, compared to its average volume of 750,101. Enovis Co. has a fifty-two week low of $29.32 and a fifty-two week high of $56.43. The firm has a market cap of $2.00 billion, a P/E ratio of -15.99 and a beta of 1.86. The company has a quick ratio of 1.12, a current ratio of 2.27 and a debt-to-equity ratio of 0.40. The firm has a 50 day moving average of $36.70 and a two-hundred day moving average of $41.98.

Enovis (NYSE:ENOV - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The company reported $0.98 earnings per share for the quarter, topping analysts' consensus estimates of $0.92 by $0.06. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The company had revenue of $560.98 million during the quarter, compared to analysts' expectations of $555.14 million. Sell-side analysts forecast that Enovis Co. will post 2.79 EPS for the current year.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.